KPC 34

Drug Profile

KPC 34

Alternative Names: KPC-34

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kucera Pharmaceutical
  • Class Antineoplastics; Phospholipids; Pyrimidine nucleosides; Ribonucleosides
  • Mechanism of Action DNA synthesis inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Acute lymphoblastic leukaemia in USA (PO)
  • 01 Apr 2017 Preclinical trials in Acute myeloid leukaemia in USA (PO)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Acute myloid leukaemia presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top